QuantaMatrix퀀타매트릭스

QuantaMatrix remains deeply loss-making with revenue of about ₩3.1B over the trailing twelve months, while its shares have fallen sharply over the past year.

QuantaMatrix is a Korean diagnostics company selling blood-based and sepsis-related test devices mainly to hospitals in Korea and overseas. Trailing twelve-month operating losses of about ₩16.6B far exceed revenue of ₩3.1B, and free cash flow is negative at about ₩16.9B. The share price is ₩2,260, down 46.1% over one year, and the company's latest filings mention a name change and convertible bond activity.

What stands out

• Trailing twelve-month operating margin is -526.8% and net margin is -567.5%, so costs are far above sales.
• Borrowings of about ₩7.0B exceed cash of about ₩4.6B, and liabilities are 34.7% of equity.
• Revenue grew 47.7% in 2025 to ₩3.7B, but operating losses remained large at ₩15.6B.
• The fair value model in the data gives a base case of ₩120 and a bear case of ₩306, well below the current price, and no bull value is provided.
• Foreign ownership is unchanged at 18.6% over 60 days, and 20-day foreign net flows were positive while institutions were net sellers.

What to watch

• Filings on the planned company name change, the convertible bond transactions and the shareholder meeting outcomes.
• Whether the Alzheimer's testing expansion described in the latest news produces revenue growth, which the data does not yet show.
• Future half-year or quarterly results for signs of narrowing losses and cash burn; the data does not include forecasts.